Home | Business News | Browse by Publication | B | Biotech Business

NEW TEST MAY PREDICT BREAST CANCER METASTASIS.

Article Excerpt
Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified a new marker for breast cancer metastasis called TMEM, for Tumor Microenvironment of Metastasis. As reported in the online edition of the journal Clinical Cancer Research, density of TMEM was associated with the development of distant organ metastasis via the bloodstream -- the most common cause of death from breast cancer.

The National Cancer Institute (NCI)--funded translational study could lead to the first test to predict the likelihood of breast cancer metastasis via the bloodstream -- a development that could change the way breast cancer is treated.

An estimated 40 percent of breast cancer patients relapse and develop metastatic disease. About 40,000 women die of metastatic breast cancer every year.

"Currently, anyone with a breast cancer diagnosis fears the worst -- that the cancer will spread and threaten their lives. A tissue test for metastatic risk could alleviate those worries, and prevent toxic and costly measures...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!